Catherine Tralau-Stewart, PhD

Title(s)Associate Professor, Bioengineering
SchoolSchool of Pharmacy
vCardDownload vCard
    Other Positions
    Title(s)Director, CTSI T1 Translational Research

    Collapse Biography 
    Collapse Education and Training
    University College LondonPhD1986Medicine
    Collapse Awards and Honors
    Royal Society of Chemistry (London)2012Fellowship

    Collapse Overview 
    Collapse Overview
    Cathy has over 25 years experience of drug discovery in Industry and academia. She was Associate Director of Pharmacology for the Respiratory Inflammation CEDD GlaxoSmithKline, responsible for Respiratory and Inflammation lead optimization activities. She is a Pharmacologist with a wide experience of a number of therapeutic areas (i.e. Oncology, Inflammatory diseases, Respiratory, Cardiovascular, Rheumatology, Gastroenterology, Infection), including leading interdisciplinary projects from Target identification through to Clinical Proof of Concept and to Phase III/IV clinical studies. She has been involved in leading project teams, which identified of over 20 development compound candidates and >10 marketed small molecule and biological drugs.

    Cathy led the development of innovative academic-industry drug discovery models in the UK and has recently published a review of UK academic drug discovery (Nature Reviews Drug Discovery 13, Jan 2014). She founded, managed and developed a successful and innovative interdisciplinary research drug discovery centre (DDC) at Imperial College London. Cathy is a founder of a number of spinout companies progressing DDC projects towards the clinic.

    Since moving to California in February 2013, Cathy has been an advisor to UCSF CTSI and Stanford SPARK programmes, is Director of Ginkgo Consulting, and has recently joined the CTSI Early Translational Research therapeutics track.

    Collapse ORNG Applications 
    Collapse Websites
    Collapse In The News
    Collapse Featured Videos

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Fiedler LR, Chapman K, Xie M, Maifoshie E, Jenkins M, Golforoush PA, Bellahcene M, Noseda M, Faust D, Jarvis A, Newton G, Paiva MA, Harada M, Stuckey DJ, Song W, Habib J, Narasimham P, Aqil R, Sanmugalingam D, Yan R, Pavanello L, Sano M, Wang SC, Sampson RD, Kanayaganam S, Taffet GE, Michael LH, Entman ML, Tan TH, Harding SE, Low CMR, Tralau-Stewart C, Perrior T, Schneider MD. MAP4K4 Inhibition Promotes Survival of Human Stem Cell-Derived Cardiomyocytes and Reduces Infarct Size In Vivo. Cell Stem Cell. 2019 Mar 01. PMID: 30853557.
      View in: PubMed
    2. Tornatore L, Sandomenico A, Raimondo D, Low C, Rocci A, Tralau-Stewart C, Capece D, D'Andrea D, Bua M, Boyle E, van Duin M, Zoppoli P, Jaxa-Chamiec A, Thotakura AK, Dyson J, Walker BA, Leonardi A, Chambery A, Driessen C, Sonneveld P, Morgan G, Palumbo A, Tramontano A, Rahemtulla A, Ruvo M, Franzoso G. Cancer-selective targeting of the NF-?B survival pathway with GADD45ß/MKK7 inhibitors. Cancer Cell. 2014 Oct 13; 26(4):495-508. PMID: 25314077; PMCID: PMC4197335.
    3. Fiedler L, Chapman K, Maifoshie E, Low C, Tralau-Stewart C, Schneider M.Heart. 157 Approaches for Pharmacological Inhibition of Cardiac Cell Death:MAP4K4 as a Therapeutic Target. 2014; Suppl 3(100):A91 doi: 10.1136/heartjnl-2014.
    4. Tralau-Stewart C, Low CM, Marlin N. UK academic drug discovery. Nat Rev Drug Discov. 2014 Jan; 13(1):15-6. PMID: 24378794.
      View in: PubMed
    5. Zhao H, Luo X, Zhou Z, Liu J, Tralau-Stewart C, George AJ, Ma D. Early treatment with xenon protects against the cold ischemia associated with chronic allograft nephropathy in rats. Kidney Int. 2014 Jan; 85(1):112-23. PMID: 24025645.
      View in: PubMed
    6. Zhao H, Yoshida A, Xiao W, Ologunde R, O'Dea KP, Takata M, Tralau-Stewart C, George AJ, Ma D. Xenon treatment attenuates early renal allograft injury associated with prolonged hypothermic storage in rats. FASEB J. 2013 Oct; 27(10):4076-88. PMID: 23759444.
      View in: PubMed
    7. Zhao H, Watts HR, Chong M, Huang H, Tralau-Stewart C, Maxwell PH, Maze M, George AJ, Ma D. Xenon treatment protects against cold ischemia associated delayed graft function and prolongs graft survival in rats. Am J Transplant. 2013 Aug; 13(8):2006-18. PMID: 23710625; PMCID: PMC3884761.
    8. James C. Collins, Alan Armstrong, Kathryn L. Chapman, Hayley C. Cordingley, Albert A. Jaxa-Chamiec, Katie E. Judd, David J. Mann, Katherine A. Scott, Catherine J. Tralau-Stewart and Caroline M. R. Low.Prospective use of molecular field points in ligand-based virtual screening: efficient identification of new reversible Cdc25 inhibitors. 2013.
    9. Cathy Tralau-Stewart & Caroline Low.Funding Emergency. Pan European Networks Government 2. 2012; (2).
    10. Cathy Tralau-Stewart & Albertb Jaxa-Chamiec.Partnering for drugs. Public Service Review. UK Science & Technology Issue 1 Oct 2011. 2011; (1).
    11. Giamas G, Filipovic A, Jacob J, Messier W, Zhang H, Yang D, Zhang W, Shifa BA, Photiou A, Tralau-Stewart C, Castellano L, Green AR, Coombes RC, Ellis IO, Ali S, Lenz HJ, Stebbing J. Kinome screening for regulators of the estrogen receptor identifies LMTK3 as a new therapeutic target in breast cancer. Nat Med. 2011 Jun; 17(6):715-9. PMID: 21602804.
      View in: PubMed
    12. Nials AT, Tralau-Stewart CJ, Gascoigne MH, Ball DI, Ranshaw LE, Knowles RG. In vivo characterization of GSK256066, a high-affinity inhaled phosphodiesterase 4 inhibitor. J Pharmacol Exp Ther. 2011 Apr; 337(1):137-44. PMID: 21205924.
      View in: PubMed
    13. Tralau-Stewart CJ, Williamson RA, Nials AT, Gascoigne M, Dawson J, Hart GJ, Angell AD, Solanke YE, Lucas FS, Wiseman J, Ward P, Ranshaw LE, Knowles RG. GSK256066, an exceptionally high-affinity and selective inhibitor of phosphodiesterase 4 suitable for administration by inhalation: in vitro, kinetic, and in vivo characterization. J Pharmacol Exp Ther. 2011 Apr; 337(1):145-54. PMID: 21205923.
      View in: PubMed
    14. Tralau-Stewart CJ, Wyatt CA, Kleyn DE, Ayad A. Drug discovery: new models for industry-academic partnerships. Drug Discov Today. 2009 Jan; 14(1-2):95-101. PMID: 18992364.
      View in: PubMed
    15. Procopiou PA, Biggadike K, English AF, Farrell RM, Hagger GN, Hancock AP, Haase MV, Irving WR, Sareen M, Snowden MA, Solanke YE, Tralau-Stewart CJ, Walton SE, Wood JA. Novel glucocorticoid antedrugs possessing a 17beta-(gamma-lactone) ring. J Med Chem. 2001 Feb 15; 44(4):602-12. PMID: 11170650.
      View in: PubMed
    16. Barr H, Chatlani P, Tralau CJ, MacRobert AJ, Boulos PB, Bown SG. Local eradication of rat colon cancer with photodynamic therapy: correlation of distribution of photosensitiser with biological effects in normal and tumour tissue. Gut. 1991 May; 32(5):517-23. PMID: 2040475; PMCID: PMC1378929.
    17. Barr H, MacRobert AJ, Tralau CJ, Boulos PB, Bown SG. The significance of the nature of the photosensitizer for photodynamic therapy: quantitative and biological studies in the colon. Br J Cancer. 1990 Nov; 62(5):730-5. PMID: 2147108; PMCID: PMC1971516.
    18. Barr H, Tralau CJ, Boulos PB, MacRobert AJ, Krasner N, Phillips D, Bown SG. Selective necrosis in dimethylhydrazine-induced rat colon tumors using phthalocyanine photodynamic therapy. Gastroenterology. 1990 Jun; 98(6):1532-7. PMID: 2338191.
      View in: PubMed
    19. CJ Tralau, H Barr, AJ MacRobert & SG Bown .Photodynamic Therapy of Neoplastic DiseaseVol I (D Kessel). Relative merits of porphyrin and phthalocyanine sensitisation in photodynamic therapy. 1990; 263-277.
    20. Matthewson K, Barr H, Tralau C, Bown SG. Low power interstitial Nd YAG laser photocoagulation: studies in a transplantable fibrosarcoma. Br J Surg. 1989 Apr; 76(4):378-81. PMID: 2720347.
      View in: PubMed
    21. Tralau CJ, Young AR, Walker NP, Vernon DI, MacRobert AJ, Brown SB, Bown SG. Mouse skin photosensitivity with dihaematoporphyrin ether (DHE) and aluminium sulphonated phthalocyanine (AlSPc): a comparative study. Photochem Photobiol. 1989 Mar; 49(3):305-12. PMID: 2525261.
      View in: PubMed
    22. H Barr, CJ Tralau, AJ MacRobert, I Morrison, D Phillips & SG Bown .Fluorescence photometric techniques for determination of microscopic tissue distribution of phthalocyanine sensitisers for photodynamic therapy. Lasers in Medical Science. 1988; 3:81-86.
    23. Tralau CJ, Barr H, Sandeman DR, Barton T, Lewin MR, Bown SG. Aluminum sulfonated phthalocyanine distribution in rodent tumors of the colon, brain and pancreas. Photochem Photobiol. 1987 Nov; 46(5):777-81. PMID: 3441500.
      View in: PubMed
    24. Barr H, Tralau CJ, Boulos PB, MacRobert AJ, Tilly R, Bown SG. The contrasting mechanisms of colonic collagen damage between photodynamic therapy and thermal injury. Photochem Photobiol. 1987 Nov; 46(5):795-800. PMID: 3441502.
      View in: PubMed
    25. Barr H, Tralau CJ, MacRobert AJ, Krasner N, Boulos PB, Clark CG, Bown SG. Photodynamic therapy in the normal rat colon with phthalocyanine sensitisation. Br J Cancer. 1987 Aug; 56(2):111-8. PMID: 3663462; PMCID: PMC2002142.
    26. Tralau CJ, MacRobert AJ, Coleridge-Smith PD, Barr H, Bown SG. Photodynamic therapy with phthalocyanine sensitisation: quantitative studies in a transplantable rat fibrosarcoma. Br J Cancer. 1987 Apr; 55(4):389-95. PMID: 3580264; PMCID: PMC2001712.
    27. Bown SG, Tralau CJ, Smith PD, Akdemir D, Wieman TJ. Photodynamic therapy with porphyrin and phthalocyanine sensitisation: quantitative studies in normal rat liver. Br J Cancer. 1986 Jul; 54(1):43-52. PMID: 2942166; PMCID: PMC2001658.
    Catherine's Networks
    Derived automatically from this person's publications.
    People in Profiles who have published with this person.
    Similar People
    People who share similar concepts with this person.
    Same Department